All News

Biologics have become the standard of care for rheumatoid arthritis (RA) that fails to respond adequately to conventional disease-modifying antirheumatic agents (DMARDs), and overall, these agents are safe and effective. However, an association between treatment with anti–tumor necrosis factor (anti-TNF) agents and new-onset psoriasis in patients with RA has been observed.

Prior to the launch of solriamfetol (Sunosi) for narcolepsy and obstructive sleep apnea, the Drug Enforcement Administration designated it as a Schedule IV drug, indicating that it has a low potential for abuse and a low risk of dependence. Around the same time, results from the phase 3 TONES 3 study were published, showing the drug’s efficacy in increasing wakefulness and reducing sleepiness.

While pulmonary rehabilitation (PR) is an evidence-based and cost-effective treatment for people with chronic obstructive pulmonary disease (COPD), uptake of and compliance with this intervention has been poor. For patients who decline PR, inspiratory muscle training (IMT), which involves strengthening the inspiratory muscles by increasing their workload, may be an option, particularly as it can be performed in the home instead of in a clinic.

Health plans on the Affordable Care Act (ACA) exchanges will be required to display quality ratings starting with the 2020 plan year, according to an announcement from CMS, which is expanding the 5-star rating system it uses on Medicare plans to the health insurance exchanges.

This week, the top managed care stories included the Trump administration looking to bar legal immigrants from using public benefits; a study in The American Journal of Managed Care® finding that a law to limit surprise medical bills is working; data on Affordable Care Act enrollment showing the effect of subsidies.

The August issue of The American Journal of Managed Care® (AJMC®) featured research on surprise medical billing policies, social determinants of health, and the value of chimeric antigen receptor T-cell therapies, among other topics. Here are 5 findings from research published in the issue.

Generic drug makers are being accused of blocking a Congressional probe into their pricing practices; Illinois has become the first state to require insurance companies to pay for EpiPens for kids in cases of severe allergic reactions; Tufts Health Plan and Harvard Pilgrim Health will merge to create a new company covering 2.4 million people across New England.

FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment; It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated. The FDA also gave approval to entrectinib for the treatment of adults with metastatic non–small cell lung cancer whose tumors are ROS1 positive.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo